Estrogens
and Methyltestosterone (Estratest, Estratest H.S.)
|
Category:
Description:
-
Estrogen
and Androgen combination hormone replacement
-
Estratest:
1.25mg esterified estrogens, 2.5mg methyltestosterone
-
Estratest
H.S.: 0.625mg esterified estrogens, 1.25mg methyltestosterone
Indications:
Contraindications:
-
Known
or suspected breast cancer (except those being treated for metastatic
disease)
-
Known
or suspected estrogen-dependent neoplasia
-
Known
or suspected pregnancy
-
Undiagnosed
abnormal genital bleeding
-
Current
or history of thrombophlebitis, thrombosis, thromboembolic disorders
(except when used in breast or prostatic cancer treatment).
Precautions:
-
Pregnancy
category X
-
Use
with caution in nursing mothers and patients with hypertension,
diabetes, asthma, epilepsy, migraine, cardiac or renal dysfunction,
history of depression, pre-existing uterine leiomyotoma, history of
jaundice during pregnancy, impaired liver function, metabolic bone
disorders and in young women (and men).
-
Take
with food to avoid GI side effects.
-
May
decrease glucose intolerance in diabetic patients.
-
Discontinue
therapy and contact health care provider if pregnancy is suspected.
-
Rule
out breast cancer prior to initiating treatment.
-
May
cause irreversible androgenic effects (hirsutism, decreased breast
size, deepening of voice, clitoral hypertrophy)
Adverse
Reactions (Side Effects):
-
Rash,
acne, alopecia, nausea
-
Abnormal
menstrual bleeding, changes in cervical secretions
-
Edema,
weight change
-
Depression,
insomnia, somnolence
-
Androgenic:
acne, oily kin/hair, weight gain, mild hirsutism, decreased breast
size, deepening of voice, clitoral hypertrophy, testicular hypotrophy
-
Hypoestrogenic:
flushing, sweating, vaginitis, nervousness, emotional disorders
-
Hepatic
dysfunction
-
CNS:
dizziness, headache, sleep disorders, fatigue
-
Muscle
cramps, joint pain and swelling
|
Dosage:
For more information on the use of conjugated estrogens and
methyltestosterone, read:
|
Source:
Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
|